Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating, because that oh-so-familiar routine of meetings, deadlines, and whatnot has, of course, returned. But what can you do? The world keeps spinning which, after all, is a good thing. So with this glass-half-full approach in mind, time to fire up the coffee kettle, quaff a cup or three of stimulation, and dig in for another busy day. On that note, here are some tidbits. Hope your journey progresses nicely and, as always, do keep in touch …
Novartis (NVS) is abandoning an effort to gain U.S. regulatory approval for a biosimilar of Rituxan, a Roche (RHHBY) drug to treat certain cancer and rheumatoid arthritis. The decision comes after the Food and Drug Administration sought additional information to support the medicine, which is already approved in the European Union, Switzerland, Japan, and Australia. Rituxan is a monoclonal antibody used in non-Hodgkin’s lymphoma and rheumatoid arthritis; it had more than $4 billion in sales in the U.S. in 2016.
About the Author Reprints
